Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 5/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.32 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | IDH2 | P48735 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21872990 | 0.91 | AAK1 (0.32) | IDH1IRAK4 | |
| SCHEMBL21906344 | 0.83 | CSF1R (0.45) | IDH1IRAK4 | |
| SCHEMBL21906297 | 0.82 | CSF1R (0.43) | IDH1IRAK4FGFR1 | |
| SCHEMBL21873077 | 0.77 | IRAK4 (0.32) | IDH1IRAK4 | |
| SCHEMBL21873001 | 0.75 | CSF1R (0.44) | IDH1IRAK4 | |
| SCHEMBL28339583 | 0.74 | — | — | |
| SCHEMBL21873038 | 0.74 | CSF1R (0.43) | IRAK4FGFR1 | |
| SCHEMBL21873025 | 0.68 | MAPK8 (0.33) | IDH1CSNK2A1IRAK4 | |
| SCHEMBL21873024 | 0.65 | CSF1R (0.44) | IDH1 | |
| SCHEMBL21872975 | 0.65 | CCNB2 (0.38) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180495-B2 | Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-11-23 | — | — | US | disclosed |
| CN-110461841-B | Nitrogen heteroaryl derivative with CSF1R inhibitory activity, and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2020-09-15 | — | — | CN | disclosed |
| US-20200140431-A1 | NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2020-05-07 | — | — | US | disclosed |
| CN-110461841-A | A kind of azepine aryl derivatives, preparation method and application with CSF1R inhibitory activity | ABBISKO THERAPEUTICS CO LTD | 2019-11-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140431-A1 | NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | CSF1R, CSF3R, FSHR | IDH1 668/4885CSNK2A2 3654/4885CSNK2B 3359/4885 |
| US-11180495-B2 | Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof | CSF1R, CSF3R, FSHR | IDH1 668/4885CSNK2A2 3654/4885CSNK2B 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.